Back to Journals » Drug Design, Development and Therapy » Volume 9

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance

Authors Wang G, Liu Y, Qiu P, Zhou S, Xu L, Wen P, Wen J, Xiao X

Received 24 August 2014

Accepted for publication 28 January 2015

Published 2 June 2015 Volume 2015:9 Pages 2839—2846

DOI https://doi.org/10.2147/DDDT.S73150

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Prof. Dr. Wei Duan


Guiliang Wang,1,2 Yan Liu,2 Ping Qiu,1 Shu-Feng Zhou,3,4 Linfang Xu,1 Ping Wen,1 Jianbo Wen,1 Xianzhong Xiao5

1Department of Digestive Internal Medicine, Gannan Medical University Pingxiang Hospital, Pingxiang, People’s Republic of China; 2Department of Digestive Internal Medicine, 307 Hospital of PLA, Beijing, People’s Republic of China; 3Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA; 4Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guiyang Medical University, Guiyang, People’s Republic of China; 5Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, People’s Republic of China

Abstract: The purpose of this study was to analyze the cost-effectiveness of lamivudine (LMV), telbivudine (LdT), and entecavir (ETV) in treatment of chronic hepatitis B with adefovir dipivoxil (ADV) resistance. Two hundred and fifty-two patients were recruited and screened for resistance to ADV and randomly assigned into three groups: LMV + ADV, LdT + ADV, and ETV + ADV. The ratio of biochemical response, virological response, seroconversion of hepatitis Be antigen (HBeAg)/hepatitis Be antibody (HBeAb), viral breakthrough, and the cost and effectiveness of treatments were analyzed. A comparison of the results of the ratio of biochemical response, virological response and seroconversion of HBeAg/HBeAb, showed no statistical difference between the three groups, with the economic cost of LMV + ADV the lowest, LdT + ADV the middle, and ETV + ADV the highest. The side effects of the three plans are all rare and tolerable. LMV + ADV is the optimal rescue strategy, and LdT + ADV the alternative selection in the economically less developed regions, while ETV + ADV was used in the economically developed regions.

Keywords: chronic hepatitis B, adefovir dipivoxil, lamivudine, telbivudine, entecavir, resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]